Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: January 12, 2010
Last updated: November 21, 2014
Last verified: October 2014

This clinical trial is studying how well giving cilengitide together with sunitinib malate works in treating patients with advanced solid tumors or glioblastoma multiforme. Cilengitide and sunitinib malate may stop the growth of tumor cells by blocking blood flow to the tumor. Giving cilengitide together with sunitinib malate may kill more tumor cells. Studying samples of blood in the laboratory from patients receiving cilengitide and sunitinib malate may help doctors understand the effect of these drugs on biomarkers.

Condition Intervention Phase
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Adult Solid Neoplasm
Recurrent Adult Brain Neoplasm
Drug: Cilengitide
Other: Clinical Observation
Other: Laboratory Biomarker Analysis
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pilot Biomarker Study of the Integrin AlphavBeta3 Antagonist Cilengitide (EMD121974) in Combination With Sunitinib

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Change in serum VEGFR2 [ Time Frame: Over 14 days from the end of sunitinib to the end of course 1 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Comparison of the change in serum VEGFR2 in courses 1 and 2 [ Time Frame: Over 14 days ] [ Designated as safety issue: No ]
    Compared using a paired t-test.

  • Toxicity rates, graded using the NCI CTCAE version 4.0 [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: Yes ]
    Compared using chi-squared tests or Fisher exact tests, as appropriate.

  • Response rate evaluated using RECIST criteria [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: No ]
    Summarized by type, grade, and attribution and compared using chi-squared tests or Fisher exact tests, as appropriate.

  • Serum type I collagen c-telopeptide crosslink measurements [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: No ]
  • Progression-free survival [ Time Frame: Assessed up to 30 days after completion of study treatment ] [ Designated as safety issue: No ]
    Estimated using the Kaplan-Meier method. Summarized by type, grade, and attribution and compared using chi-squared tests or Fisher exact tests, as appropriate.

Enrollment: 41
Study Start Date: December 2009
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I (course 1)
Patients receive cilengitide IV over 1 hour twice weekly for 2 weeks.
Drug: Cilengitide
Given IV
Other Name: EMD 121974
Other: Laboratory Biomarker Analysis
Correlative studies
Arm II (course 1)
Patients do not receive treatment and undergo a 2-week rest period.
Other: Clinical Observation
Patients undergo a 2-week rest period
Other Name: observation
Other: Laboratory Biomarker Analysis
Correlative studies

Detailed Description:


I. Determine the effect of cilengitide on changes in serum VEGFR2, a pharmacodynamic biomarker of sunitinib malate effects on endothelial function, during the withdrawal phase of a course of sunitinib malate in patients with advanced solid tumors or glioblastoma multiforme.


I. Determine the effect of cilengitide exposure on changes in VEGFR2 over the 14-day interval from the end of sunitinib malate administration to the end of course 1 in these patients.

II. Test the safety and efficacy of this regimen in these patients. III. Develop serum collagen c-telopeptide crosslinks (CTx) as a pharmacodynamic marker for cilengitide.


COURSE I: Patients receive oral sunitinib malate on days 1-14 (weeks 1-2). Patients are then randomized to 1 of 2 treatment arms.

ARM I: Patients receive cilengitide IV over 1 hour twice in weeks 3 and 4.

ARM II: Patients do not receive treatment in weeks 3 and 4.

COURSE II: Patients in both arms then receive oral sunitinib malate on days 1-14 and cilengitide IV over 1 hour twice in weeks 3 and 4. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up periodically.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed solid tumor or malignant glioblastoma multiforme meeting >= 1 of the following criteria:

    • Disease refractory to standard therapy
    • No standard therapy exists
    • Sunitinib malate monotherapy would be appropriate management
  • Measurable disease is not required
  • Previously treated brain metastases or primary brain neoplasms allowed provided patient is not receiving concurrent corticosteroids
  • Karnofsky performance status 70-100%
  • Absolute neutrophil count (ANC) >= 1,500/μL
  • White blood cell count (WBC) >= 3,000/μL
  • Platelet count >= 100,000/μL
  • Hemoglobin >= 9 g/dL
  • Total bilirubin normal (unless due to documented Gilbert syndrome)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal (ULN) (< 5 times ULN in the presence of liver metastases)
  • Creatinine normal OR creatinine clearance >= 60 mL/min
  • Serum calcium =< 12.0 mg/dL
  • QTc < 500 msec
  • Patients with any of the following are allowed provided they have New York Heart Association (NYHA) class I-II cardiac function and undergo a baseline echocardiogram (ECHO)/multiple gated acquisition (MUGA):

    • History of class II heart failure and asymptomatic on treatment
    • Prior anthracycline exposure
    • Previously treated with central thoracic radiotherapy that included the heart in the radiotherapy port
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib malate
  • No concurrent uncontrolled illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Psychiatric illness and/or social situation that would limit compliance with study requirements
  • No pre-existing thyroid abnormality for which thyroid function cannot be maintained in the normal range with medication
  • No documented thrombosis (pulmonary embolism or deep vein thrombosis) within the past 6 months
  • No known coagulopathy or thrombophilia
  • No proven gastric or duodenal ulcer or clinically significant gastrointestinal (GI) blood loss within the past 6 weeks
  • No history of central nervous system (CNS) hemorrhage
  • No life-threatening bleeding diathesis within the past 6 months
  • No history of serious ventricular arrhythmia (i.e., ventricular fibrillation or ventricular tachycardia >= 3 beats in a row) or other significant electrocardiogram (ECG) abnormalities
  • No poorly controlled hypertension (i.e., systolic blood pressure (BP) >= 150 mm Hg or diastolic BP >= 100 mm Hg)
  • No condition that would impair the ability to swallow and retain sunitinib malate tablets, including any of the following:

    • GI tract disease resulting in an inability to take oral medications or a requirement for IV alimentation
    • Prior surgical procedures affecting absorption
    • Active peptic ulcer disease
  • No gastrostomy, jejunostomy, or other forms of enteral tube feeding modalities
  • None of the following conditions:

    • Serious or non-healing wound or ulcer
    • Abdominal fistula, GI perforation, or intra-abdominal abscess within the past 28 days
    • Cerebrovascular accident or transient ischemic attack within the past 12 months
    • Myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within the past 12 months
    • NYHA class III or IV heart failure
    • Radiographically or physiologically diagnosed usual interstitial pneumonitis (UIP) or non-specific interstitial pneumonitis (NSIP)
  • No bone fracture within the past 12 months
  • No other concurrent anticancer agents or therapies
  • More than 4 weeks since prior radiotherapy or systemic antineoplastic therapy (6 weeks for nitrosoureas, mitomycin C, or bevacizumab) and recovered
  • More than 2 weeks since prior hormone replacement therapy or hormonal contraceptives
  • More than 1 month since prior surgery
  • At least 7 days since prior and no concurrent CYP3A4 inhibitors
  • At least 12 days since prior and no concurrent CYP3A4 inducers
  • Prior luteinizing hormone-releasing hormone agonists for hormone-refractory prostate cancer allowed
  • Prior antiangiogenic agents (e.g., sorafenib, pazopanib, AZD2171 [cediranib maleate], PTK787 [vatalanib], or VEGF Trap [ziv-aflibercept]) allowed provided there is no disease progression
  • No prior cilengitide or sunitinib malate
  • No prior bevacizumab
  • No other concurrent investigational agents
  • No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients
  • No concurrent agents with proarrhythmic potential (e.g., terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, or flecainide)
  • No concurrent palliative radiotherapy
  • No other concurrent chemotherapy or biologic agents
  • No concurrent medications that may cause QTc prolongation
  • No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g., warfarin)

    • Up to 2 mg of daily warfarin for the prophylaxis of thrombosis allowed
    • Low-molecular weight heparin allowed provided prothrombin time (PT)/international normalized ratio (INR) =< 1.5
  • No concurrent grapefruit juice
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01122888

United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
Principal Investigator: Michael Maitland University of Chicago
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI) Identifier: NCT01122888     History of Changes
Other Study ID Numbers: NCI-2011-01455, NCI-2011-01455, CDR0000659080, UCCRC-09-259-A, 09-259-A, 8313, U01CA069852, P30CA014599
Study First Received: January 12, 2010
Last Updated: November 21, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Brain Neoplasms
Brain Diseases
Central Nervous System Diseases
Central Nervous System Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Nervous System Diseases
Nervous System Neoplasms
Neuroectodermal Tumors processed this record on November 24, 2014